by 27

BY27 是一种具有强效性和选择性的 BET BD2 抑制剂（Ki：3.1 nM），具有抗癌活性，抑制 BRD2、BRD3、BRD4 和 BRDT 的 BD1/BD2，抑制肿瘤生长。

BPO-27 racemate (BPO-27(racemate)) 是一种CFTR 抑制剂，IC50为8 nM。

HS-27 是一种荧光束缚的 Hsp90 抑制剂，SNX-5422 通过 PEG 接头束缚在异硫氰酸荧光素或 FITC 上。 HS-27 可用于“即看即治”模式。

SM27 是一种成纤维细胞生长因子 2（FGF2） 抑制剂，具有抗血管生成活性，可用于研究肿瘤。

BAY-27-9955 is a glucagon receptor antagonist.

Gap 27是一种合成的 connexin43 模拟肽，是一种间隙连接抑制剂。它与通往第二跨膜连接蛋白区段的第二细胞外环的一部分具有保守的序列同源性。

FGIN 1-27 是一种吲哚乙酰胺，是外周苯二氮卓受体的特异性的配体，Ki 为 5.0 nM。FGIN 1-27 可以透过血脑屏障。FGIN 1-27对异烟肼引起的抽搐发作具有抑制作用。

β-Endorphin (1-27) (human) acetate 存在于大脑垂体和下丘脑中，具有镇痛活性。 β-Endorphin (1-27) (human) acetate 是一种阿片受体激动剂，对 μ-阿片受体和 δ-阿片受体具有较好的亲和力。

BRD4 Inhibitor-27 是一种有效的 BRD4 抑制剂，对 BRD4 BD1 和 BRD4 BD2 具有抑制作用， IC50 分别为 9.6 和 11.3 μM。BRD4 Inhibitor-27 具有抗癌活性，可用于研究乳腺癌。

AChE-IN-27是一种用于高通量测定的小分子。

Compound 55052-27-2是一个片段分子，CAS号为55052-27-2，可作为分子拼接、扩展和修饰的重要骨架，为新型候选药物的设计与筛选提供结构基础与研究工具，常用于药物发现、药物合成等相关研究。

Compound 4265-27-4是一个片段分子，CAS号为4265-27-4，可作为分子拼接、扩展和修饰的重要骨架，为新型候选药物的设计与筛选提供结构基础与研究工具，常用于药物发现、药物合成等相关研究。

FLT3-IN-27（compound 49）作为FLT3-ITD抑制剂，其IC50仅为174 nM。该化合物可有效抑制细胞增长，引起细胞周期在G1期的阻滞，主要应用于急性髓系白血病的相关研究。

HDAC-IN-27 dihydrochloride (Compound 11h) 是一种有效的口服活性选择性HDACI抑制剂，对HDAC1-3的IC50值为0.43至3.01 nM。此外，HDAC-IN-27 dihydrochloride 在体内和体外均展现出抗癌活性。该化合物对急性髓系白血病 (AML) 细胞系表现出强抗增殖活性，并通过诱导细胞凋亡 (apoptosis) 和组蛋白乙酰化 (AcHH3和AcHH4) 发挥作用，对于急性髓系白血病 (AML) 的研究具有重要潜力。

AKT-IN-27 (4a) 是一种潜在的抗癌药物，通过选择性靶向Akt驱动的信号通路起作用。此化合物诱导细胞凋亡，机制包括激活半胱天冬酶-3 (caspase-3)、诱导 G2/M 期细胞周期阻滞，以及破坏线粒体膜电位。AKT-IN-27 (4a) 可用于三阴性乳腺癌 (TNBC) 的研究。

ATX inhibitor 27 (Compound 31) 是一种ATX抑制剂，对人体自分泌运动因子 (hATX) 和溶血磷脂酰胆碱 (LPC) 的IC50分别为13 nM与23 nM。通过抑制ATX酶，ATX inhibitor 27 能有效降低体内LPA水平。此化合物可用于研究ATX-LPA相关的疾病，如炎症、神经退行性疾病和癌症。

4-oxo-27-TBDMS Withaferin A is a derivative of the steroidal lactone withaferin A that has anticancer activity.1 It is cytotoxic to A2780 ovarian cancer cells (IC50 = 17 μM) but not to carboplatin-resistant A2780 (A2780/CP70) cells (IC50 = >100 μM). It is selective for A2780 cells over non-cancerous ARPE19 cells (IC50 = 1,660 μM). 4-oxo-27-TBDMS Withaferin A induces DNA fragmentation in A2780 cells.References1. Perestelo, N.R., Llanos, G.G., Reyes, C.P., et al. Expanding the chemical space of withaferin A by incorporating silicon to improve its clinical potential on human ovarian carcinoma cells. J. Med. Chem. 62(9), 4571-4585 (2019). 4-oxo-27-TBDMS Withaferin A is a derivative of the steroidal lactone withaferin A that has anticancer activity.1 It is cytotoxic to A2780 ovarian cancer cells (IC50 = 17 μM) but not to carboplatin-resistant A2780 (A2780/CP70) cells (IC50 = >100 μM). It is selective for A2780 cells over non-cancerous ARPE19 cells (IC50 = 1,660 μM). 4-oxo-27-TBDMS Withaferin A induces DNA fragmentation in A2780 cells. References1. Perestelo, N.R., Llanos, G.G., Reyes, C.P., et al. Expanding the chemical space of withaferin A by incorporating silicon to improve its clinical potential on human ovarian carcinoma cells. J. Med. Chem. 62(9), 4571-4585 (2019).

Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, SK-N-MC, and T47D cells). In vivo, in newborn pigs, PACAP (6-27) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-27) and PACAP (1-38) . It also inhibits PACAP (1-27)-stimulated increases in plasma insulin and glucagon levels and pancreatic venous blood flow in dogs when administered locally to the pancreas at a dose of 500 μg.

CCK (27-33) is a C-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety. Non-sulfated CCK (27-33) inhibits binding of [3H]naloxone in rat cerebellum membranes (IC50 = 4 uM) and inhibits electrically-stimulated contraction of isolated guinea pig ileum (IC50 = 17 uM), an effect that can be reversed by naloxone. Unlike sulfated CCK (27-33), the non-sulfated form does not reduce exploratory behavior in mice when administered at doses up to 1 uMol/kg.

β-Endorphin (1-27) is an endogenous peptide that binds to μ-, δ-, and κ-opioid receptors (Kis = 5.31, 6.17, and 39.82 nM, respectively, in COS-1 cells expressing rat receptors). It binds to rat and mouse brain membrane preparations (IC50s = 1.1 and 5.7 nM, respectively) and induces chemotaxis of human monocytes in vitro when used at a concentration of 1 nM. Intracerebroventricular administration of β-endorphin (1-27) increases the latency to tail withdrawal in response to thermal stimulation in mice with a median antinociceptive dose (AD50) of 1,500 pmol per animal. It inhibits antinociception induced by β-endorphin in mice in response to thermal stimuli when administered at a dose of 65 pmol per animal. In rats, β-endorphin (1-27) does not affect drug-associated place preference when administered at doses up to 20 μg, i.c.v., but inhibits β-endorphin-induced place preference when administered at a dose of 10 μg per animal.

Antitubercular agent-27 (compound 1) 是一种有效的抗结核药剂，IC50值为 3.2 μM，MICb> 值为 7.8 μM，IC90值为 7.0 μM。Antitubercular agent-27 对结核分枝杆菌 H37Rv 的耐药分离株显示出抗分枝杆菌活性。Antitubercular agent-27 显示出有效的细胞内抗分枝杆菌活性和低细胞毒性。

SARS-CoV-2-IN-27 为具有扩展长度的双臂二磷酸 C6 烷基酯分子镊子，显示出针对 SARS-CoV-2 的抗病毒活性。其抑制 SARS-CoV-2 活力的 IC50 为 1.0 μM，针对病毒尖刺伪粒子转导的 IC50 为 1.7 μM。此外，该化合物能引起脂质体膜破坏，其 EC50 为 6.5 μM。

SARS-CoV-2-IN-27 disodium 是具有扩展长度分子镊子的双臂二磷酸C6烷基酯。它显示出抗病毒活性，分别在抑制SARS-CoV-2活性和病毒尖刺伪粒子转导方面的IC50为1.0 μM和1.7 μM。此外，SARS-CoV-2-IN-27 disodium能引起脂质体膜破坏，其EC50为6.5 μM。

GRP (14-27) (human, porcine, canine) 表现为铃蟾肽受体配体。其特异性结合受到 GTP 和 GDP 的抑制作用，但 GMP 对此无影响。